Neurocrine Biosciences (BSP:N1BI34) Cyclically Adjusted Book per Share: R$3.93 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:N1BI34 Neurocrine Biosciences Inc BSP:N1BI34
94 GF Score
Price R$42.92
GF Value R$51.84
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Cyclically Adjusted Book per Share?

Neurocrine Biosciences BSP:N1BI34 94 Cyclically Adjusted Book per Share is R$3.93 as of Jun. 2026. GuruFocus rates BSP:N1BI34 with a GF Score™ of 94/100 and a GF Value™ of R$51.84 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Neurocrine Biosciences's adjusted book value per share for the three months ended in Jun. 2026 was R$9.314. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$3.93 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Neurocrine Biosciences's average Cyclically Adjusted Book Growth Rate was 24.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 24.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 27.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Neurocrine Biosciences was 31.30% per year. The lowest was -18.70% per year. And the median was -2.70% per year.

As of today (2026-08-06), Neurocrine Biosciences's current stock price is R$42.92. Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was R$3.93. Neurocrine Biosciences's Cyclically Adjusted PB Ratio of today is 10.92.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Neurocrine Biosciences was 47.47. The lowest was 7.19. And the median was 16.02.


Neurocrine Biosciences  (BSP:N1BI34) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Neurocrine Biosciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=42.92/3.93
=10.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Neurocrine Biosciences was 47.47. The lowest was 7.19. And the median was 16.02.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Neurocrine Biosciences Cyclically Adjusted Book per Share Related Terms


Neurocrine Biosciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Cyclically Adjusted Book per Share Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 2.01 2.36 3.75 4.13

Neurocrine Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.66 3.68 4.13 4.02 3.93

BSP:N1BI34 vs VTRS, UTHR, ELAN: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PB Ratio falls into.


BSP:N1BI34
94GF Score
Neurocrine Biosciences Inc BSP:N1BI34
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Neurocrine Biosciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=9.314/333.9520*333.9520
=9.314

Current CPI (Jun. 2026) = 333.9520.

Neurocrine Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.658 241.428 0.910
201612 0.608 241.432 0.841
201703 0.442 243.801 0.605
201706 0.645 244.955 0.879
201709 0.615 246.819 0.832
201712 0.690 246.524 0.935
201803 0.665 249.554 0.890
201806 0.787 251.989 1.043
201809 1.014 252.439 1.341
201812 1.028 251.233 1.366
201903 0.861 254.202 1.131
201906 1.019 256.143 1.329
201909 1.285 256.759 1.671
201912 1.417 256.974 1.841
202003 1.844 258.115 2.386
202006 2.314 257.797 2.998
202009 2.325 260.280 2.983
202012 3.098 260.474 3.972
202103 3.595 264.877 4.533
202106 3.400 271.696 4.179
202109 3.748 274.310 4.563
202112 4.094 278.802 4.904
202203 3.624 287.504 4.209
202206 3.758 296.311 4.235
202209 4.214 296.808 4.741
202212 4.641 296.797 5.222
202303 4.499 301.836 4.978
202306 4.608 305.109 5.044
202309 5.035 307.789 5.463
202312 5.540 306.746 6.031
202403 5.907 312.332 6.316
202406 6.697 314.175 7.119
202409 7.439 315.301 7.879
202412 7.948 315.605 8.410
202503 7.379 319.799 7.706
202506 7.549 322.561 7.816
202509 8.078 324.800 8.306
202512 8.865 324.054 9.136
202603 8.858 330.213 8.958
202606 9.314 333.952 9.314

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of R$3.93 mean?
Neurocrine Biosciences (BSP:N1BI34) has a Cyclically Adjusted Book per Share of R$3.93 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Cyclically Adjusted Book per Share too high?
Neurocrine Biosciences' current Cyclically Adjusted Book per Share is R$3.93. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Cyclically Adjusted Book per Share compare to VTRS and UTHR?
Neurocrine Biosciences' Cyclically Adjusted Book per Share of R$3.93 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Cyclically Adjusted Book per Share is R$3.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (BSP:N1BI34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$51.84, compared to a current price of R$42.92 — trading 17.2% below its estimated fair value. The current Cyclically Adjusted Book per Share is R$3.93. Neurocrine Biosciences' overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Neurocrine Biosciences (BSP:N1BI34), the current Cyclically Adjusted Book per Share is R$3.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (BSP:N1BI34) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of R$42.92 is trading 17.2% below its estimated GF Value™ of R$51.84. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for BSP:N1BI34:

  • Cyclically Adjusted Book per Share: R$3.93
  • GF Value™: R$51.84 vs. price of R$42.92 (17.2% below fair value)
  • GF Score™: 94/100 with 4 warning signs

No single metric tells the full story. See the BSP:N1BI34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for BSP:N1BI34

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$42.92
Price
R$51.84
GF Value